Research from D. Debruin and co-authors yields new data on testicular cancer
2009 JUL 27 - (NewsRx.com) -- In this recent study, researchers in Netherlands conducted a study "To compare the semen quality and hormonal status between patients with testicular cancer and normal versus increased serum levels of beta-hCG. Retrospective study. Academic research environment." "All 203 patients with testicular cancer who required chemotherapy in the period 1995-2003 were included. In 107 patients semen samples were stored by cryopreservation; 62 patients could be analyzed because both semen was stored and hormones were determined before starting chemotherapy (median age 25 years, range 17-49 years). Total motile sperm count, T, E-2, LH, FSH, and PRL. Total motile sperm count was decreased in patients with increased beta-hCG (median 11.9 x 10(6)) compared with patients with normal beta-hCG (median 21.5 x 10(6)). Testosterone, E-2, and PRL were significantly higher in patients with increased beta-hCG levels, whereas LH and FSH were lower. Semen quality was significantly and negatively correlated with beta-hCG, E-2, and PRL. Patients with increased beta-hCG had an inferior spermatogenesis compared with patients with normal beta-hCG," wrote D. Debruin and colleagues. The researchers concluded: "Increased beta-hCG appears to be associated with impaired spermatogenesis and increased levels of E-2 and PRL. (Fertil Steril (R) 2009;91:2481-6." Debruin and colleagues published their study in Fertility and Sterility (Semen quality in men with disseminated testicular cancer: relation with human chorionic gonadotropin beta-subunit and pituitary gonadal hormones. Fertility and Sterility, 2009;91(6):2481-2486). For more information, contact D. Debruin, Hanzepl 1, NL-9713 GZ Groningen, Netherlands. Publisher contact information for the journal Fertility and Sterility is: Elsevier Science Inc., 360 Park Avenue South, New York, NY 10010-1710, USA. Keywords: Netherlands, Chemotherapy, Chorionic, Chorionic Gonadotropin, Clinical Trials, Drug Therapy, Drugs, Gonadotropin, Hormones, Oncology, Pharmaceuticals, Post-Trials Research, Spermatogenesis, Testicular Cancer, Testicular Diseases, Treatment. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.
|
